Latest data from the Hong Kong Stock Exchange shows that on November 3, Chairman Li Qiling purchased an additional 52,000 shares of DAWNRAYS PHARMA (02348) at HK$1.22 per share, totaling approximately HK$63,400. Following this transaction, Li's total holdings reached approximately 711 million shares, representing a 47.26% stake. The transaction also involved another related party: Xiong Rongli.